Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.


Slider News


  • 2023 - 01 - 30

    Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations

  • 2023 - 02 - 08

    Menarini Group are with the Turkish and Syrian populations

  • 2023 - 02 - 21

    Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO<sup>®</sup> (selinexor)

  • 2023 - 03 - 14

    Neoplasia a Cellule Dendritiche Plasmacitoidi Blastiche: Aifa approva Tagraxofusp prima e unica terapia contro tumore del sangue raro e aggressivo

  • 2023 - 04 - 13

    The Dates of the XXVII Edition of the International Fair Play Menarini Awards

  • 2023 - 04 - 19

    Menarini announces an exclusive distribution agreement for Boditech’s AFIAS-10 system

  • 2023 - 05 - 02

    The doors of Europe open wide for the Volpi Rosse Menarini

  • 2023 - 05 - 04

    Birth rate emergency, younger generations say: “It’s not just an issue of economic stability”

  • 2023 - 05 - 09

    Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting

  • 2023 - 05 - 14

    Botticelli, the inquietude and the beauty

  • 2023 - 05 - 26

    Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU<sup>®</sup> (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

  • 2023 - 06 - 08

    Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

  • 2023 - 06 - 19

    Fair Play Menarini International Awards announces the winners of the XXVII edition at CONI

  • 2023 - 06 - 27

    Fair Play Menarini International Awards, young swimmer Gianluca Gensini wins the ‘Fiamme Gialle’ special “Studio and Sport” award

  • 2023 - 07 - 02

    Fair Play Menarini International Awards, the 2023 edition starts with the talk show “The Champions tell their Stories” in Piazza della Signoria, Florence

  • 2023 - 07 - 03

    Great news at the Fair Play Menarini International Awards, tennis player Francesca Schiavone among the winners of the 2023 edition

  • 2023 - 07 - 04

    Fair Play Menarini International Awards, excitement is building for the awards ceremony after the “The Champions Tell their Stories”

  • 2023 - 07 - 05

    Fair Play Menarini International Awards, the champions of Fair Play cast their spell on the audience in Fiesole

  • 2023 - 07 - 21

    Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer

  • 2023 - 08 - 30

    The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

  • 2023 - 09 - 20

    European Commission Approves Menarini Group’s ORSERDU<sup>®</sup> (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

  • 2023 - 10 - 18

    The 2023 Season gets underway for the Volpi Rosse Menarini Wheelchair Basketball Team

  • 2023 - 10 - 19

    European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

  • 2023 - 11 - 07

    Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

  • 2023 - 11 - 20

    Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology

  • 2023 - 12 - 08

    Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer

  • 2023 - 12 - 11

    Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)